secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001824293-25-000094
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports positive interim biomarker data from Phase 2a IPF study; IDMC recommends continuation
--------------------------------------------------------------------------------

- 6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.
- IDMC recommended study continue as planned; no safety concerns seen to date.
- Phase 2a study fully enrolled; topline data expected Q3 2025.
- GRI-0621 patients demonstrated increased basement membrane remodeling and potential repair mechanism vs control.
- Additional pulmonary function test results expected in coming weeks; flow cytometry and gene expression data later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/0001824293-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/val-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001824293-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer